ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.331,39
-0,25%
S&P 500
5.469,30
0,39%
US Dollar vs BRL
5,4516
-0,01%
Bitcoin
61.282,65
-0,85%
Brent Oil
84,985
0,95%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vallon Pharmaceuticals Inc (VLON)

  7. Vallon Pharmaceuticals Inc (VLON) Notícias

VLON

Vallon Pharmaceuticals (VLON)

Vallon Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VLON
DataHoraFonteTítuloCódigoCompanhia
18/06/202417:54Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
18/06/202417:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
20/05/202417:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VLONVallon Pharmaceuticals Inc
17/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VLONVallon Pharmaceuticals Inc
10/05/202418:24Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VLONVallon Pharmaceuticals Inc
10/05/202417:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VLONVallon Pharmaceuticals Inc
09/05/202417:31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VLONVallon Pharmaceuticals Inc
02/02/202418:21Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VLONVallon Pharmaceuticals Inc
20/12/202319:12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VLONVallon Pharmaceuticals Inc
14/08/202317:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VLONVallon Pharmaceuticals Inc
06/07/202317:28Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VLONVallon Pharmaceuticals Inc
08/06/202307:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:VLONVallon Pharmaceuticals Inc
07/06/202317:19Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:VLONVallon Pharmaceuticals Inc
30/05/202318:02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:VLONVallon Pharmaceuticals Inc
26/05/202317:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:VLONVallon Pharmaceuticals Inc
26/05/202317:20Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:VLONVallon Pharmaceuticals Inc
26/05/202317:17Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:VLONVallon Pharmaceuticals Inc
15/05/202318:15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:VLONVallon Pharmaceuticals Inc
27/04/202310:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VLONVallon Pharmaceuticals Inc
25/04/202317:20Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:VLONVallon Pharmaceuticals Inc
25/04/202314:54Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:VLONVallon Pharmaceuticals Inc
24/04/202319:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VLONVallon Pharmaceuticals Inc
21/04/202312:55GlobeNewswire Inc.Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.NASDAQ:VLONVallon Pharmaceuticals Inc
20/04/202319:45GlobeNewswire Inc.Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitNASDAQ:VLONVallon Pharmaceuticals Inc
12/04/202317:06Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:VLONVallon Pharmaceuticals Inc
12/04/202317:05GlobeNewswire Inc.Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023NASDAQ:VLONVallon Pharmaceuticals Inc
04/04/202310:00GlobeNewswire Inc.Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETNASDAQ:VLONVallon Pharmaceuticals Inc
24/02/202309:30GlobeNewswire Inc.Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsNASDAQ:VLONVallon Pharmaceuticals Inc
24/02/202308:10Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:VLONVallon Pharmaceuticals Inc
24/02/202308:09Edgar (US Regulatory)Annual Report (10-k)NASDAQ:VLONVallon Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VLON

Seu Histórico Recente

NASDAQ
PULTX
Putnam Ultra Short Mac S...
LSE
AW94
Citi Fun 25
USOTC
BICMF
BIC Camera (PK)
AMEX
OTD
O2 Diesel
NASDAQ
NCTY
The9
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados